Skip to main
PEN
PEN logo

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 35%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra Inc demonstrated significant growth in December, achieving its highest volume of VTE procedures ever and a remarkable 41% growth attributed to the Flash 2.0 product gaining market share. The company reported an increase in non-GAAP operating margin by 200 basis points year-over-year, driven by improvements in gross margin and reduced R&D expenses, culminating in an operating margin of 15.1%. Additionally, the overall Thrombectomy sales reached $222.7 million, reflecting a 16.9% increase, while gross margins improved to 67.4%, further highlighting the company’s financial health and operational efficiency.

Bears say

The analysis of Penumbra Inc presents a negative outlook primarily due to anticipated revenue growth decreasing to below 12%, attributed to weaker-than-expected contributions from new products and slow improvements in profitability. Additionally, the revised revenue estimates for 2025 and 2026 reflect a decline, adjusting from $1.363 billion to $1.349 billion and from $1.545 billion to $1.531 billion, respectively. Several risks further exacerbate this situation, including competitive pressures, margin challenges, delayed product clearances, and potential disruptions in supply chain or manufacturing processes.

Penumbra (PEN) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 35% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Buy based on their latest research and market trends.

According to 20 analysts, Penumbra (PEN) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $286.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $286.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.